-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: Da Niu Mao in the medical world
On July 8, 2021, the U.
More than 40 million patients with Alzheimer's disease worldwide
More than 40 million patients with Alzheimer's disease worldwideWith the advent of global aging, the prevalence of Alzheimer's disease is also increasing year by year
The Safety Risk That Cannot Be Ignored--The Trash Can Hypothesis
The Safety Risk That Cannot Be Ignored--The Trash Can HypothesisAs an antibody, the pharmacological mechanism of aducanumab is to selectively bind to β-amyloid, thereby eliminating amyloid in the brain of patients with Alzheimer's disease
Here, aducanumab, as an antibody against brain amyloid-like proteins, we can understand that its target is this kind of precipitated protein in the brain, which is slowly stored by the human brain after long-term negative accumulation.
However, this may create a new problem! It is this trash can that carries this rubbish, how can it be transported out of the brain? As we all know, there is a blood-brain barrier in the brain, and substance delivery is extremely difficult to pass
Further there is a metabolic risk of pharmacokinetics
Further there is a metabolic risk of pharmacokineticsGenerally speaking, after various antibodies bind to the target, they will be slowly decomposed in the body along with the substances it binds
summary
summaryIn short, the development of a new drug for Alzheimer's disease has never been truly successful before.
